PSC ‐ DM : A Validated Clinical Diagnostic Model for Distinguishing Primary From Secondary Sclerosing Cholangitis

BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is a rare, progressive cholangiopathy for which diagnosis remains challenging because of the absence of disease-specific markers and the presence of secondary causes of sclerosing cholangitis (SSC) that closely mimic its clinical presentation. Diagnostic uncertainty can delay appropriate management and add to the psychological burden experienced by patients. This study aimed to identify clinical parameters that support the early and accurate differentiation of PSC from SSC. METHODS: We conducted a multicentre retrospective study of adults with an established diagnosis of PSC or SSC. Independent predictors of PSC were identified using multivariable logistic regression and externally validated in an independent cohort. RESULTS: In the derivation cohort (n = 234, 155 PSC, 79 SSC), six variables were independently associated with PSC diagnosis, including younger age at presentation (p < 0.0001), presence of IBD (p < 0.0001), absence of prior hepato-pancreato-biliary surgery (p < 0.0001), autoimmune comorbidities (p = 0.0038), family history of autoimmune diseases (p = 0.0086), and absence of pancreatic abnormalities (p = 0.0338). These variables were used to develop the PSC diagnostic model (PSC-DM). In the external validation cohort (n = 142, 98 PSC, 44 SSC), the AUROC of PSC-DM was 0.95 (95% CI 0.91-0.98). In an exploratory analysis, PSC-DM significantly improved non-expert diagnostic accuracy (94.3% versus 78.6%, p = 0.0023). CONCLUSIONS: PSC-DM is a simple, externally validated clinical prediction model that accurately distinguishes PSC from SSC using routinely available clinical variables. It may support initial diagnostic assessment in non-specialist settings, facilitate timely referral to expert centres and improve patient selection for clinical trials.

Authors

Institutions

Publication Details

Journal
Liver International
Published
2026-09-30
DOI
https://doi.org/10.1111/liv.70892
Primary Topic
Liver Diseases and Immunity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

PSC ‐ DM : A Validated Clinical Diagnostic Model for Distinguishing Primary From Secondary Sclerosing Cholangitis

Federica Malinverno, Rodrigo Vieira Motta, Armando Curto, Cesare Maino et al.
Liver International
Liver Diseases and Immunity
article

PSC ‐ DM : A Validated Clinical Diagnostic Model for Distinguishing Primary From Secondary Sclerosing Cholangitis

Federica Malinverno, Rodrigo Vieira Motta, Armando Curto, Cesare Maino, Marco Carbone, Emma Louise Culver, Francesca Bolis, Alessio Gerussi, Daphne D’Amato, Laura Cristoferi, Pietro Invernizzi, Miki Scaravaglio, Kris V. Kowdley, Alberto Marini, Eugenia Nofit, Camilla Gallo, Stephen J. Rossi, Raffaella Viganò, Eugenia Pesatori, Alessandra Nardi, Mauro Viganò
article en

Abstract

BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is a rare, progressive cholangiopathy for which diagnosis remains challenging because of the absence of disease-specific markers and the presence of secondary causes of sclerosing cholangitis (SSC) that closely mimic its clinical presentation. Diagnostic uncertainty can delay appropriate management and add to the psychological burden experienced by patients. This study aimed to identify clinical parameters that support the early and accurate differentiation of PSC from SSC. METHODS: We conducted a multicentre retrospective study of adults with an established diagnosis of PSC or SSC. Independent predictors of PSC were identified using multivariable logistic regression and externally validated in an independent cohort. RESULTS: In the derivation cohort (n = 234, 155 PSC, 79 SSC), six variables were independently associated with PSC diagnosis, including younger age at presentation (p < 0.0001), presence of IBD (p < 0.0001), absence of prior hepato-pancreato-biliary surgery (p < 0.0001), autoimmune comorbidities (p = 0.0038), family history of autoimmune diseases (p = 0.0086), and absence of pancreatic abnormalities (p = 0.0338). These variables were used to develop the PSC diagnostic model (PSC-DM). In the external validation cohort (n = 142, 98 PSC, 44 SSC), the AUROC of PSC-DM was 0.95 (95% CI 0.91-0.98). In an exploratory analysis, PSC-DM significantly improved non-expert diagnostic accuracy (94.3% versus 78.6%, p = 0.0023). CONCLUSIONS: PSC-DM is a simple, externally validated clinical prediction model that accurately distinguishes PSC from SSC using routinely available clinical variables. It may support initial diagnostic assessment in non-specialist settings, facilitate timely referral to expert centres and improve patient selection for clinical trials.

Liver InternationalVol. 46(11)
University of Rome Tor Vergata (IT), Wellcome/MRC Cambridge Stem Cell Institute (GB), University of Cambridge (GB), John Radcliffe Hospital (GB), National Institute for Health and Care Research (GB), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Ospedale Papa Giovanni XXIII (IT), Azienda Ospedaliera San Gerardo (IT), Liver Institute Northwest (US), Oxford BioMedica (United Kingdom) (GB), PSC Partners Seeking a Cure (US), University of Florence (IT), University of Milano-Bicocca (IT), Washington State University (US)
Good health and well-being
Openalex Percentile: Top 14%
Liver Diseases and Immunity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.